Gyre Therapeutics (GYRE) Net Cash Flow (2010 - 2026)
Gyre Therapeutics (GYRE) reported Net Cash Flow of $166000.0 for Q1 2026, down 94.78% year-over-year from $3.2 million in Q1 2025, and up 104.83% on a QoQ basis from -$3.4 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Net Cash Flow data on file, last reported at $166000.0 in Q1 2026.
- Quarterly Net Cash Flow fell 94.78% year-over-year to $166000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.9 million (up 250.3% YoY) and the FY2025 annual result came in at $24.9 million, up 216.25% from the prior year.
- Net Cash Flow grew to $166000.0 in Q1 2026 per GYRE's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $40.6 million in Q2 2022 and bottomed at -$52.3 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$3.4 million (2025), against an average of -$2.1 million.
- The widest annual swing landed in 2022, when Net Cash Flow plunged 261.62%; it then jumped 1203.26% in 2025.
- Tracing GYRE's Net Cash Flow over 5 years: stood at -$26.9 million in 2022, then jumped by 174.15% to $19.9 million in 2023, then sank by 119.05% to -$3.8 million in 2024, then gained by 9.58% to -$3.4 million in 2025, then surged by 104.83% to $166000.0 in 2026.
- Per Business Quant, the three latest GYRE Net Cash Flow figures stand at $166000.0 (Q1 2026), -$3.4 million (Q4 2025), and $3.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 166,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 166,000.00 |
| Mar 31, 2026 | 166,000.00 |
| Dec 31, 2025 | -3.43 Mn |
| Dec 31, 2025 | -3.43 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 21.44 Mn |
| Jun 30, 2025 | 21.44 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Sep 30, 2024 | -337,000.00 |
| Sep 30, 2024 | -337,000.00 |
| Jun 30, 2024 | -13.61 Mn |
| Jun 30, 2024 | -13.61 Mn |
| Mar 31, 2024 | -3.68 Mn |
| Mar 31, 2024 | -3.68 Mn |
| Dec 31, 2023 | 19.94 Mn |
| Dec 31, 2023 | 19.94 Mn |
| Sep 30, 2023 | 704,000.00 |
| Sep 30, 2023 | 704,000.00 |
| Jun 30, 2023 | -7.02 Mn |
| Jun 30, 2023 | -7.02 Mn |
| Mar 31, 2023 | -4.99 Mn |
| Mar 31, 2023 | -4.99 Mn |
| Dec 31, 2022 | -26.89 Mn |
| Dec 31, 2022 | -26.89 Mn |
| Sep 30, 2022 | -52.30 Mn |
| Sep 30, 2022 | -52.30 Mn |
| Jun 30, 2022 | 40.58 Mn |
| Jun 30, 2022 | 40.58 Mn |
| Mar 31, 2022 | -9.53 Mn |
| Mar 31, 2022 | -9.53 Mn |
| Dec 31, 2021 | -14.81 Mn |
| Dec 31, 2021 | -14.81 Mn |
| Sep 30, 2021 | -14.46 Mn |
| Sep 30, 2021 | -14.46 Mn |
| Jun 30, 2021 | -9.42 Mn |
| Jun 30, 2021 | -9.42 Mn |
| Mar 31, 2021 | 52.68 Mn |
| Mar 31, 2021 | 52.68 Mn |
| Dec 31, 2020 | 5.44 Mn |
| Dec 31, 2020 | 5.44 Mn |
| Sep 30, 2020 | -34.35 Mn |
| Sep 30, 2020 | -34.35 Mn |
| Jun 30, 2020 | -11.09 Mn |
| Jun 30, 2020 | -11.09 Mn |
| Mar 31, 2020 | 55.00 Mn |
| Mar 31, 2020 | 55.00 Mn |
| Dec 31, 2019 | -7.65 Mn |
| Dec 31, 2019 | -7.65 Mn |
| Sep 30, 2019 | 5.62 Mn |
| Sep 30, 2019 | 5.62 Mn |
| Jun 30, 2019 | -7.68 Mn |
| Jun 30, 2019 | -7.68 Mn |
| Mar 31, 2019 | -6.19 Mn |
| Mar 31, 2019 | -6.19 Mn |
| Dec 31, 2018 | -4.79 Mn |
| Dec 31, 2018 | -4.79 Mn |
| Sep 30, 2018 | -10.66 Mn |
| Sep 30, 2018 | -10.66 Mn |
| Jun 30, 2018 | -80.02 Mn |
| Jun 30, 2018 | -80.02 Mn |
| Mar 31, 2018 | 106.92 Mn |
| Mar 31, 2018 | 106.92 Mn |
| Dec 31, 2017 | 3.10 Mn |
| Dec 31, 2017 | 3.10 Mn |
| Sep 30, 2017 | -21.69 Mn |
| Sep 30, 2017 | -21.69 Mn |
| Jun 30, 2017 | 10.99 Mn |
| Jun 30, 2017 | 10.99 Mn |
| Mar 31, 2017 | -2.46 Mn |
| Mar 31, 2017 | -2.46 Mn |
| Dec 31, 2016 | 947,000.00 |
| Dec 31, 2016 | 947,000.00 |
| Sep 30, 2016 | -2.02 Mn |
| Sep 30, 2016 | -2.02 Mn |
| Jun 30, 2016 | -9.40 Mn |
| Jun 30, 2016 | -9.40 Mn |
| Mar 31, 2016 | -8.52 Mn |
| Mar 31, 2016 | -8.52 Mn |
| Dec 31, 2015 | 6.00 Mn |
| Dec 31, 2015 | 6.00 Mn |
| Sep 30, 2015 | 20.79 Mn |
| Sep 30, 2015 | 20.79 Mn |
| Jun 30, 2015 | 237,000.00 |
| Jun 30, 2015 | 237,000.00 |
| Mar 31, 2015 | 525,000.00 |
| Mar 31, 2015 | 525,000.00 |
| Dec 31, 2014 | -2.06 Mn |
| Dec 31, 2014 | -2.06 Mn |
| Sep 30, 2014 | 11.84 Mn |
| Sep 30, 2014 | 11.84 Mn |
| Jun 30, 2014 | -1.62 Mn |
| Jun 30, 2014 | -1.62 Mn |
| Mar 31, 2014 | -9.44 Mn |
| Mar 31, 2014 | -9.44 Mn |
| Dec 31, 2013 | 19.93 Mn |
| Dec 31, 2013 | 19.93 Mn |
| Sep 30, 2013 | -1.32 Mn |
| Sep 30, 2013 | -1.32 Mn |
| Jun 30, 2013 | -6.80 Mn |
| Jun 30, 2013 | -6.80 Mn |
| Mar 31, 2013 | -12.38 Mn |
| Mar 31, 2013 | -12.38 Mn |
| Dec 31, 2012 | 4.04 Mn |
| Dec 31, 2012 | 4.04 Mn |
| Sep 30, 2012 | 6.56 Mn |
| Sep 30, 2012 | 6.56 Mn |
| Jun 30, 2012 | -17.02 Mn |
| Jun 30, 2012 | -17.02 Mn |
| Mar 31, 2012 | -18.62 Mn |
| Mar 31, 2012 | -18.62 Mn |
| Dec 31, 2011 | -23.26 Mn |
| Dec 31, 2011 | -23.26 Mn |
| Sep 30, 2011 | -37.60 Mn |
| Sep 30, 2011 | -37.60 Mn |
| Jun 30, 2011 | 29.31 Mn |
| Jun 30, 2011 | 29.31 Mn |
| Mar 31, 2011 | -27.02 Mn |
| Mar 31, 2011 | -27.02 Mn |
| Dec 31, 2010 | -19.95 Mn |
| Dec 31, 2010 | -19.95 Mn |
| Sep 30, 2010 | -35.83 Mn |
| Sep 30, 2010 | -35.83 Mn |